908 Devices Inc. (NASDAQ:MASS) Position Reduced by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP decreased its holdings in shares of 908 Devices Inc. (NASDAQ:MASS) by 3.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 384,332 shares of the company’s stock after selling 12,707 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.10% of 908 Devices worth $845,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. LPL Financial LLC raised its holdings in shares of 908 Devices by 13.0% in the 4th quarter. LPL Financial LLC now owns 63,287 shares of the company’s stock worth $139,000 after purchasing an additional 7,295 shares in the last quarter. Geode Capital Management LLC boosted its position in 908 Devices by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 581,300 shares of the company’s stock worth $1,279,000 after acquiring an additional 13,512 shares during the period. Prudential Financial Inc. purchased a new position in 908 Devices during the fourth quarter valued at approximately $34,000. Concurrent Investment Advisors LLC acquired a new position in 908 Devices in the 4th quarter valued at approximately $52,000. Finally, Barclays PLC boosted its position in 908 Devices by 452.7% during the third quarter. Barclays PLC now owns 46,214 shares of the company’s stock valued at $160,000 after purchasing an additional 37,853 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Mark Spoto purchased 10,000 shares of 908 Devices stock in a transaction that occurred on Wednesday, May 14th. The shares were acquired at an average price of $4.29 per share, for a total transaction of $42,900.00. Following the transaction, the director now directly owns 62,971 shares in the company, valued at approximately $270,145.59. This represents a 18.88% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 27.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of 908 Devices in a research report on Saturday, May 10th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, 908 Devices currently has a consensus rating of “Moderate Buy” and an average target price of $5.33.

908 Devices Stock Performance

908 Devices stock opened at $4.58 on Friday. The business’s 50-day simple moving average is $4.60 and its 200-day simple moving average is $3.27. The firm has a market capitalization of $163.69 million, a PE ratio of -2.59 and a beta of 0.26. 908 Devices Inc. has a 52 week low of $1.81 and a 52 week high of $7.03.

908 Devices (NASDAQ:MASS) last released its earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.05. 908 Devices had a negative net margin of 109.11% and a negative return on equity of 24.60%. The business had revenue of $11.78 million during the quarter, compared to analysts’ expectations of $11.90 million. Research analysts forecast that 908 Devices Inc. will post -1.99 earnings per share for the current year.

908 Devices Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.